Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of rheum australe root in preparing medicine for treating cerebral hemorrhage or reducing same caused by rtPA thrombolytic therapy after cerebral ischemia

A technology of trizaperine and cerebral ischemia, applied in the field of biopharmaceuticals, can solve problems that have not been seen yet, and achieve the effects of reducing the risk of bleeding, improving cerebral hemorrhage, and protecting blood vessels

Active Publication Date: 2018-02-02
KPC PHARM INC +1
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there has been no report on the use of trizaperine to reduce cerebral hemorrhage caused by rtPA thrombolysis after cerebral ischemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rheum australe root in preparing medicine for treating cerebral hemorrhage or reducing same caused by rtPA thrombolytic therapy after cerebral ischemia
  • Application of rheum australe root in preparing medicine for treating cerebral hemorrhage or reducing same caused by rtPA thrombolytic therapy after cerebral ischemia
  • Application of rheum australe root in preparing medicine for treating cerebral hemorrhage or reducing same caused by rtPA thrombolytic therapy after cerebral ischemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1 Study on the protective effect of tristilbene on hemorrhagic transformation in rats with cerebral ischemia-reperfusion induced by rtPA

[0041] 1. Reagents and animals

[0042] 1.1 Test product: Trizastilbene for injection, Kunming Pharmaceutical Group Co., Ltd., traits: off-white loose lumps; specifications: 20mg / bottle; batch number: 170101; storage conditions: room temperature, dark; expiration date: 2019.12. 31;

[0043]1.2 Reference substance: name or code: alteplase (rtPA); Boehringer Ingelheim (Germany); traits: off-white loose lumps; specification: 20mg / bottle (including diluent); batch number: 607009; Storage conditions: 2-8°C, airtight, away from light; expiration date: 2019.05.31;

[0044] 1.3 Other reagents: Hemoglobin Quantitative Kit (BioAssay Systems, USA, Cat: DIHB-250); MMP9 ELISA Detection Kit (R&D, USA, Cat: RMP900); Rat TNF-αELISA Detection Kit (abcam, USA, Cat: ab100785); rat IL-1βELISA detection kit (abcam, USA, Cat: ab100768).

[004...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of bio-pharmaceuticals, in particular to application of rheum australe root in preparing medicine for treating cerebral hemorrhage or reducing the same caused by rtPA thrombolytic therapy after cerebral ischemia. Researches show that activation of MMP-9 and overexpression of inflammatory factors like IL-1 beta and TNF alpha induced by rtPA in an ischemia condition can be reduced by the rheum australe root; measuring of four indicators of thrombin shows that the rheum australe root can effectively protect vascular injury caused by rtPA and lower cerebral hemorrhage risk; can inhibit thrombosis and protect blood vessels, has certain anti-coagulation effect and can effectively improve adverse effects like cerebral hemorrhage and brain tissue injurycaused by giving rtPA after cerebral ischemia so as to improve animal survival condition. Experiment results indicate that the rheum australe root has great development and application value in lowering cerebral hemorrhage risk caused by clinically using rtPA thrombolytic therapy for stroke and increasing survival rate of patients.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to the use of trizaperine in the preparation of a drug for treating cerebral hemorrhage or reducing cerebral hemorrhage caused by rtPA thrombolysis after cerebral ischemia. Background technique [0002] Studies have shown that acute ischemic stroke is one of the main causes of human disability and death; currently, domestic and foreign guidelines unanimously recommend recombinant tissue plasminogen activator (Tissue Plasminogen Activator, rtPA) intravenous thrombolysis is the treatment of acute ischemic stroke. The best solution for ischemic stroke, and the treatment within 4.5 hours of onset is the guarantee of the safety and effectiveness of thrombolysis. Therefore, thrombolysis is the only internationally recognized and effective strategy for the treatment of cerebral infarction confirmed by clinical trials. However, hemorrhagic transformation after thrombolysis is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P7/04A61P25/00
CPCA61K31/7034
Inventor 杨兆祥刘一丹龚云麒陈云建杨旭娟施凯刘国光尚建华
Owner KPC PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com